Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low …

Gastric cancer and gastro-oesophageal junction cancer represent a global health-care
challenge. Despite the efficacy of improved chemotherapy and surgical options, these …

There is an urgent need for first-line treatment options for patients with human epidermal
growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic …

Background Zolbetuximab, a monoclonal antibody targeting claudin-18 isoform 2 (CLDN18.
2), has shown efficacy in patients with CLDN18. 2-positive, human epidermal growth factor …

Oesophageal cancer is the seventh most common cancer worldwide, with 604 000 new
cases diagnosed in 2020. It is the sixth most common cause of cancer-related mortality, with …

Background The benefit of combination neoadjuvant and adjuvant chemotherapy and
immune checkpoint inhibition in patients with locally advanced, resectable gastric or gastro …

Peritoneal metastasis is the leading cause of death for gastrointestinal cancers. The native
and therapy-induced ascites ecosystems are not fully understood. Here, we characterize …

Perioperative chemotherapy is the standard treatment for locally advanced gastric or gastro-
esophageal junction cancer, and the addition of programmed cell death 1 (PD-1) inhibitor is …

Gastric adenocarcinoma, even when diagnosed at an early (localized) disease stage, poses
a major health-care burden with cure rates that remain unsatisfactorily low, particularly in …

Opinion statement The surgical treatment of gastric carcinoma has progressed significantly
in the past few decades. A major milestone was the establishment of multimodal therapies …